Vertex CEO sells 40,000 shares under 10b5-1 plan

Q: What insider transaction did VRTX CEO Reshma Kewalramani report on this Form 4?

Reshma Kewalramani reported selling 40,000 VRTX shares. The Form 4 shows multiple open-market sales of Vertex common stock totaling 40,000 shares on February 27, 2026, carried out under a pre-established Rule 10b5-1 trading plan.

Q: How many separate sale transactions are reported for the VRTX CEO in this filing?

The Form 4 shows 13 separate sale transactions. Each line represents an open-market sale of Vertex common stock on February 27, 2026, with different share amounts and weighted average prices documented in the accompanying footnotes.

Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported open-market sales of 40,000 shares of Vertex common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 trading plan entered into on November 17, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported open-market sales of 40,000 shares of Vertex common stock on February 27, 2026 under a pre-arranged Rule 10b5-1 trading plan entered into on November 17, 2025. The shares were sold at prices ranging from $479.75 to $496.95, and she held 98,278 shares directly after the final transaction.

Insider Trade Summary

Net Seller: 40,000 shares

Net Sell 13 txns

Insider Kewalramani Reshma

Role CEO & President

Sold 40,000 shs ($19.74M)

Type	Security	Shares	Price	Value
Sale	Common Stock	400	$479.75	$192K
Sale	Common Stock	120	$481.50	$58K
Sale	Common Stock	240	$482.84	$116K
Sale	Common Stock	2,510	$487.13	$1.22M
Sale	Common Stock	3,278	$488.27	$1.60M
Sale	Common Stock	460	$489.32	$225K
Sale	Common Stock	2,725	$490.54	$1.34M
Sale	Common Stock	949	$491.30	$466K
Sale	Common Stock	2,520	$493.29	$1.24M
Sale	Common Stock	3,498	$494.33	$1.73M
Sale	Common Stock	15,580	$495.38	$7.72M
Sale	Common Stock	5,995	$496.16	$2.97M
Sale	Common Stock	1,725	$496.95	$857K

Holdings After Transaction: Common Stock — 98,278 shares (Direct)

Footnotes (15)

F1. Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.
F2. Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3. Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).
F4. Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).
F5. Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).
F6. Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).
F7. Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).
F8. Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).
F9. Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).
F10. Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).
F11. Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).
F12. Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).
F13. Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).
F14. Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).
F15. Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRTX CEO Reshma Kewalramani report on this Form 4?

Reshma Kewalramani reported selling 40,000 VRTX shares. The Form 4 shows multiple open-market sales of Vertex common stock totaling 40,000 shares on February 27, 2026, carried out under a pre-established Rule 10b5-1 trading plan.

At what prices did the VRTX CEO sell her shares on February 27, 2026?

The VRTX CEO’s sales occurred between $479.75 and $496.95 per share. Footnotes state these were weighted average prices for separate trades, with ranges from $479.75 up to $497.17 across the reported transactions.

How many VRTX shares did Reshma Kewalramani hold after these reported sales?

She held 98,278 Vertex shares directly after the final sale. The Form 4’s last transaction line lists 98,278 shares of common stock as the total beneficially owned following the February 27, 2026 open-market transactions.

Was the VRTX CEO’s February 27, 2026 stock sale under a Rule 10b5-1 plan?

Yes, the transactions were executed under a Rule 10b5-1 plan. A footnote explains the trades were made pursuant to a company-approved trading plan entered into on November 17, 2025, providing a prearranged schedule for potential sales.

How many separate sale transactions are reported for the VRTX CEO in this filing?

The Form 4 shows 13 separate sale transactions. Each line represents an open-market sale of Vertex common stock on February 27, 2026, with different share amounts and weighted average prices documented in the accompanying footnotes.

Does the VRTX CEO provide details on the exact prices for each individual trade?

She undertakes to provide full trade-price details upon request. A footnote states Dr. Kewalramani will provide complete information on the number of shares sold at each separate price to the SEC staff, the issuer, or any security holder who asks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/03/2026 - 04:34 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kewalramani Reshma

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		S⁽¹⁾		400	D	$479.75⁽²⁾⁽³⁾	137,878	D
Common Stock	02/27/2026		S⁽¹⁾		120	D	$481.5⁽²⁾⁽⁴⁾	137,758	D
Common Stock	02/27/2026		S⁽¹⁾		240	D	$482.84⁽²⁾⁽⁵⁾	137,518	D
Common Stock	02/27/2026		S⁽¹⁾		2,510	D	$487.13⁽²⁾⁽⁶⁾	135,008	D
Common Stock	02/27/2026		S⁽¹⁾		3,278	D	$488.27⁽²⁾⁽⁷⁾	131,730	D
Common Stock	02/27/2026		S⁽¹⁾		460	D	$489.32⁽²⁾⁽⁸⁾	131,270	D
Common Stock	02/27/2026		S⁽¹⁾		2,725	D	$490.54⁽²⁾⁽⁹⁾	128,545	D
Common Stock	02/27/2026		S⁽¹⁾		949	D	$491.3⁽²⁾⁽¹⁰⁾	127,596	D
Common Stock	02/27/2026		S⁽¹⁾		2,520	D	$493.29⁽²⁾⁽¹¹⁾	125,076	D
Common Stock	02/27/2026		S⁽¹⁾		3,498	D	$494.33⁽²⁾⁽¹²⁾	121,578	D
Common Stock	02/27/2026		S⁽¹⁾		15,580	D	$495.38⁽²⁾⁽¹³⁾	105,998	D
Common Stock	02/27/2026		S⁽¹⁾		5,995	D	$496.16⁽²⁾⁽¹⁴⁾	100,003	D
Common Stock	02/27/2026		S⁽¹⁾		1,725	D	$496.95⁽²⁾⁽¹⁵⁾	98,278	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.

2. Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

3. Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).

4. Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).

5. Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).

6. Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).

7. Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).

8. Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).

9. Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).

10. Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).

11. Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).

12. Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).

13. Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).

14. Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).

15. Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR